NORGINE B.V. and KOREA PHARMA CO., LTD. Enter Into Exclusive Licence Agreement for the Commercialisation of PLENVU® in the Republic of Korea

AMSTERDAM and SEOUL, South Korea, January 3, 2019 /PRNewswire/ — Norgine to receive a significant upfront payment and undisclosed sums in sales milestones along with double-digit percentage royalties Norgine retains full commercial rights to PLENVU® in all unlicensed countries NORGINE…

Source: https://www.prnewswire.com:443/news-releases/norgine-b-v-and-korea-pharma-co-ltd-enter-into-exclusive-licence-agreement-for-the-commercialisation-of-plenvu-r-in-the-republic-of-korea-888171036.html